Non Healing WoundsPhase 1NCT01751282
Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds
A Phase 1 study testing Stem Cell in people with Non Healing Wounds, run by Roger Williams Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to determine the effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in the treatment of non-healing wounds. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Healing Wounds
- What is being tested?
- Stem Cell
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2010to Jun 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- -
- A subject must meet the following conditions in order to be included in this trial:
- Male or female subjects 18 years of age or older with chronic wounds
- Wound present for at least 3 months with no evidence of healing
- Wound size must be less than or equal to 15 cm2 at randomization
- Subjects must understand and give written informed consent
- Subjects must agree to have biopsies performed as per protocol
Who cannot join
- The presence of the following circumstances classifies a subject as unacceptable for inclusion in this trial:
- Evidence of active infection at the wound site or around the ulcer
- Requirement for the use of systemic corticosteroids or immuno- suppressive agents
- The subject is pregnant or breast-feeding
- The subject is known to be HIV positive
- The subject is known to be Hepatitis B or C positive
Show all 12Show fewer
- Glycosylated hemoglobin A1C (HbA1C) is > 12%
- Poor nutritional status (albumin < 2.0 g/dL)
- The subject has a history of active, systemic malignancy
- Clinical evidence of bone exposure within the wound bed
- The subject has a history of noncompliance to medical regimens and is not considered reliable
- The subject is unable to understand the study evaluations and provide a written informed consent
Trial locations and contacts
1 site in 1 country.
United States1 site
Roger Williams Medical Center
Providence, Rhode Island, 02908
About this study
Official title: A Randomized, Double-Blind, Controlled Study to Evaluate the Effectiveness of the Use of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in Fibrin in the Treatment of Chronic Wounds
The purpose of this study is to determine the effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in the treatment of non-healing wounds.
Read the detailed description
Sixty-six (66) subjects are planned to be enrolled into the trial. each subject's duration of participation will be 24 weeks on therapy with a 4 week post-treatment visit. A run-in phase of 2 weeks will be required prior to randomization/enrollment.
All subjects will receive appropriate and standard care for chronic wounds, including dressings, bandages, and off-loading, if required. All subjects will receive either saline, fibrin or MSCs in fibrin using an identical double-barreled syringe to keep the blind. Therefore, subjects will then be randomized to one of three groups:
- conventional standard therapy and control saline spray
- conventional standard therapy and fibrin spray
- conventional standard therapy and MSCs (autologous bone marrow-derived mesenchymal stem cell)in fibrin spray
Screening Visit:
All inclusion and exclusion information will be reviewed to make sure that the subject is eligible for entry into the study. The following procedures will be performed during this two week period:
Biopsy - One (3 x 6 mm) biopsy will be taken from the edge of the wound for additional diagnostic tests and for culturing of cells. The second (3-4 mm) biopsy will be taken from the thigh for culturing of cells in the laboratory to assess the healing process. The thigh biopsy will then be excised by taking about 3/4 inch long by 1/4 inch wide margin from around it, and suturing it closed. The reason for this biopsy of the normal skin is so that it can be used to compare the healing process to the chronic wound.
Blood Sampling - Blood will be drawn for laboratory testing to assess the overall well-being, HIV, Hepatitis B \& C and if the subject is a woman able to bear children, to test for pregnancy.
Wound Measurements - Wound measurements will be taken to determine the size of the wound and to assess for healing.
Randomization Visit:
If the wound has not reduced significantly in size, and the subject is still eligible for the study; he/she will be assigned to a study treatment. The decision as to which treatment he/she will receive will be determined by a process called randomization. Randomization is a mathematical process used to guarantee that each participant in the study has an equal chance of being assigned to any of the treatment options available.
The treatment groups that the subject may be assigned to are as follows:
Group #1 - Conventional Therapy and Control Saline Spray -The subject will receive conventional therapy, wound measurements, photography and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically normal saline to the wound. Up to 2 additional treatments will be applied at Weeks 3 \& 6 (+ or - 2 or 3 days).
Group #2 -Conventional Therapy and Fibrin Spray - The subject will receive conventional therapy, wound measurements, photography, and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically fibrin alone to the wound. Up to 2 additional treatments will be applied at Weeks 3 \& 6 (+ or - 2 or 3 days).
Group #3 - Conventional Therapy and Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin Spray - The subject will receive conventional therapy, wound measurements, photography and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically autologous bone marrow-derived mesenchymal stem cells in fibrin. Up to 2 additional treatments will be applied at Weeks 3 \& 6 (+ or - 2 or 3 days) if your wound is not healed.
Conventional Therapy - The subject will receive standard of care and accepted conventional therapy, regardless of which of the three groups you will be randomized in. This standard of care involves the use of dressings, bandages and protective ways to increase healing of your wound.
Bone Marrow Aspirate - Depending on the treatment group that the subject is assigned to, they will have either a bone marrow aspirate and/or sham (imitation) aspirate performed at this visit.
Day 1 Treatment Visit:
All groups will receive the study treatment that was assigned at the randomization visit. Wound measurements, clinical observations, wound dressings, adverse event reporting and photography will be performed.
Weekly Follow-up Visits (Weeks 1-24):
All groups will return weekly for conventional therapy, wound measurements, clinical observations, wound dressing changes, adverse event report, and photography. Two additional study treatments will be given at Weeks 3 \& 6 (+ or - 2 or 3 days) if the wound is not healed.
Post-Treatment Follow-up Visit (Week 28):
All groups will return one month after 24 weeks of treatment for evaluation, wound measurements, and photography.
Follow-up wound Biopsies:
Participants in all three study treatment groups will be asked to have an additional biopsy of the wound edge at Week 6. This biopsy will only be taken if the wound has not healed.
- Conditions
- Non Healing Wounds
- Being tested
- Stem Cell
- Keywords
- Stem Cells, chronic wounds, fibrin, Bone marrow-derived mesenchymal stem cells
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stem CellGenetic
| Study group | Role | What they receive |
|---|---|---|
| Standard therapy and control saline spray | Placebo comparator | Conventional standard therapy and control saline spray Receives: Genetic: Stem Cell |
| standard therapy and fibrin spray | Sham comparator | Conventional standard therapy and fibrin spray Receives: Genetic: Stem Cell |
| Conventional standard therapy and MSCs | Experimental | Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray. Receives: Genetic: Stem Cell |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wound closure
Measured: 24 weeks
Secondary outcomes (1)
Overall rate of wound healing reduction
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2012 (estimated)
- Study startJun 2010
- Primary completionJun 2015
- Study completionJun 2015
Why it stopped: Left Institution where study was approved
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Healing WoundsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Roger Williams Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vincent Falanga, MD, Principal investigator, Roger Williams Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01751282
- Sponsor's protocol ID
- RO1AR06034201A1
- Status last verified
- Oct 2016
- First submitted
- 13 Dec 2012
- Last updated
- 4 Oct 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Oct 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Controlled Study to Evaluate the Effectiveness of the Use of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in Fibrin in the Treatment of Chronic Wounds
- ClinicalTrials.gov ID
- NCT01751282
- Acronym / sponsor ID
- RO1AR06034201A1
- Conditions
- Non Healing Wounds
- Keywords
- Stem Cells, chronic wounds, fibrin, Bone marrow-derived mesenchymal stem cells
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Left Institution where study was approved
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Roger Williams Medical CenterUniversity, hospital or other
- Study start
- Jun 2010
- Primary completion
- Jun 2015 (actual)
- Study completion
- Jun 2015 (actual)
- First posted
- 17 Dec 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in the treatment of non-healing wounds.
Detailed description
Sixty-six (66) subjects are planned to be enrolled into the trial. each subject's duration of participation will be 24 weeks on therapy with a 4 week post-treatment visit. A run-in phase of 2 weeks will be required prior to randomization/enrollment.
All subjects will receive appropriate and standard care for chronic wounds, including dressings, bandages, and off-loading, if required. All subjects will receive either saline, fibrin or MSCs in fibrin using an identical double-barreled syringe to keep the blind. Therefore, subjects will then be randomized to one of three groups:
- conventional standard therapy and control saline spray
- conventional standard therapy and fibrin spray
- conventional standard therapy and MSCs (autologous bone marrow-derived mesenchymal stem cell)in fibrin spray
Screening Visit:
All inclusion and exclusion information will be reviewed to make sure that the subject is eligible for entry into the study. The following procedures will be performed during this two week period:
Biopsy - One (3 x 6 mm) biopsy will be taken from the edge of the wound for additional diagnostic tests and for culturing of cells. The second (3-4 mm) biopsy will be taken from the thigh for culturing of cells in the laboratory to assess the healing process. The thigh biopsy will then be excised by taking about 3/4 inch long by 1/4 inch wide margin from around it, and suturing it closed. The reason for this biopsy of the normal skin is so that it can be used to compare the healing process to the chronic wound.
Blood Sampling - Blood will be drawn for laboratory testing to assess the overall well-being, HIV, Hepatitis B \& C and if the subject is a woman able to bear children, to test for pregnancy.
Wound Measurements - Wound measurements will be taken to determine the size of the wound and to assess for healing.
Randomization Visit:
If the wound has not reduced significantly in size, and the subject is still eligible for the study; he/she will be assigned to a study treatment. The decision as to which treatment he/she will receive will be determined by a process called randomization. Randomization is a mathematical process used to guarantee that each participant in the study has an equal chance of being assigned to any of the treatment options available.
The treatment groups that the subject may be assigned to are as follows:
Group #1 - Conventional Therapy and Control Saline Spray -The subject will receive conventional therapy, wound measurements, photography and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically normal saline to the wound. Up to 2 additional treatments will be applied at Weeks 3 \& 6 (+ or - 2 or 3 days).
Group #2 -Conventional Therapy and Fibrin Spray - The subject will receive conventional therapy, wound measurements, photography, and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically fibrin alone to the wound. Up to 2 additional treatments will be applied at Weeks 3 \& 6 (+ or - 2 or 3 days).
Group #3 - Conventional Therapy and Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin Spray - The subject will receive conventional therapy, wound measurements, photography and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically autologous bone marrow-derived mesenchymal stem cells in fibrin. Up to 2 additional treatments will be applied at Weeks 3 \& 6 (+ or - 2 or 3 days) if your wound is not healed.
Conventional Therapy - The subject will receive standard of care and accepted conventional therapy, regardless of which of the three groups you will be randomized in. This standard of care involves the use of dressings, bandages and protective ways to increase healing of your wound.
Bone Marrow Aspirate - Depending on the treatment group that the subject is assigned to, they will have either a bone marrow aspirate and/or sham (imitation) aspirate performed at this visit.
Day 1 Treatment Visit:
All groups will receive the study treatment that was assigned at the randomization visit. Wound measurements, clinical observations, wound dressings, adverse event reporting and photography will be performed.
Weekly Follow-up Visits (Weeks 1-24):
All groups will return weekly for conventional therapy, wound measurements, clinical observations, wound dressing changes, adverse event report, and photography. Two additional study treatments will be given at Weeks 3 \& 6 (+ or - 2 or 3 days) if the wound is not healed.
Post-Treatment Follow-up Visit (Week 28):
All groups will return one month after 24 weeks of treatment for evaluation, wound measurements, and photography.
Follow-up wound Biopsies:
Participants in all three study treatment groups will be asked to have an additional biopsy of the wound edge at Week 6. This biopsy will only be taken if the wound has not healed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Standard therapy and control saline spray | Placebo comparator | Genetic: Stem CellConventional standard therapy and control saline spray |
| standard therapy and fibrin spray | Sham comparator | Genetic: Stem CellConventional standard therapy and fibrin spray |
| Conventional standard therapy and MSCs | Experimental | Genetic: Stem CellConventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- -
- Male or female subjects 18 years of age or older with chronic wounds
- Wound present for at least 3 months with no evidence of healing
- Wound size must be less than or equal to 15 cm2 at randomization
- Subjects must understand and give written informed consent
Key exclusion criteria (12 listed)
- The presence of the following circumstances classifies a subject as unacceptable for inclusion in this trial:
- Evidence of active infection at the wound site or around the ulcer
- Requirement for the use of systemic corticosteroids or immuno- suppressive agents
- The subject is pregnant or breast-feeding
- The subject is known to be HIV positive
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stem Cell | Genetic | Conventional standard therapy and MSCs, Standard therapy and control saline spray, standard therapy and fibrin spray |
Primary outcome
Wound closure
Time frame: 24 weeks
1 secondary outcome
Overall rate of wound healing reduction
Time frame: 24 weeks
Results and safety
The study was stopped early (reason given: Left Institution where study was approved). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Oct 2016.
Related trials for Non Healing Wounds
Recruiting
Permanent Versus Slowly Dissolving Stitches for Non-Mesh (Shouldice) Groin Hernia Repair
Inguinal Hernia
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
RecruitingPhase 2
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
Early Rectal Cancer, Stage I Rectal Cancer
Recruiting
FITting Non-invasive Tests in Lynch Syndrome Surveillance
Colorectal Cancer
Not yet recruiting
Bassini Repair Versus Desarda Technique in Urgent Complicated Inguinal Hernia Repair
Inguinal Hernia, Incarcerated Inguinal Hernia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vincent Falanga, MD principal investigator
Roger Williams Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Stem Cell in people with Non Healing Wounds, run by Roger Williams Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Left Institution where study was approved). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wound closure (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2016.